However, so many variations among individual genomes exist that identifying mutations responsible for a specific disease has in many cases proven an insurmountable challenge. But now a new study by scientists at The Scripps Research Institute (TSRI), Scripps Health, and Scripps Translational Science Institute (STSI) reveals that by comparing the genomes of diseased patients with the genomes of people with sufficiently similar ancestries could dramatically simplify searches for harmful mutations, opening new treatment possibilities.
The work, reported recently in the journal Frontiers in Genetics: Applied Genetic Epidemiology, should speed the search for the causes of many diseases and provide critical guidance to the genomics field for maximizing the potential benefits of growing genome databases.
Much work is already under way to sequence the DNA of people suffering from diseases with unknown causes, called idiopathic conditions, to find the roots of their problems. Unlike more complex conditions such as diabetes, in some cases a limited number of genetic defects, or even a single mutation, can cause an idiopathic disease. Identifying those critical mutations can lead to effective treatments for previously mysterious problems.
The new work offers a likely filter for much of that noise. The results show that comparing a person’s DNA sequence against existing genomes for those whose ancestry is not sufficiently similar, as is typically the case, can cause serious problems. Countless differences that seem unique to a patient might instead be DNA variants carried by everyone with the same ancestry. A researcher might, for instance, identify hundreds of variants and not be able to zero in on the one responsible for a disease.
But the new results show that comparing closer ancestry matches will dramatically reduce the number of variants identified as potentially responsible for a disease, reducing a search to a workable number.
For the work, the team developed a tool called the Scripps Genome Adviser. This processing framework uses a supercomputer to incorporate a variety of databases and algorithms to identify DNA variants in a particular genome relative to reference genomes. It then uses algorithms to analyze these variants and predict whether they have any physiological effects, and if so what those might be.
The team began with nearly 60 whole human genome databases and ran three key types of computing experiments. First the researchers identified the number of variants in the reference human genomes and found that on average each has millions of variants, about 12,000 of which have functional effects. Then the scientists looked at the rates at which variants appeared in various ancestry lines.Honoring Ancestry
When the team ran the searches comparing that altered genome against a reference panel of genomes that included different ancestries, the known variant remained effectively lost in a sea of other variants. But comparison against genomes of similar ancestry dramatically reduced the number of variants identified, allowing identification of the inserted disease-causing gene.
A study published simultaneously with the Scripps team’s paper by Professor Carlos Bustamante and colleagues from Stanford University also pointed to ancestry’s importance, but this is the first time a team has been able to look at the problem on the whole-genome scale. “Others have indeed recognized ancestry as important,” said Schork, “but no one had shown how much it could haunt a particular study, especially on a whole genome basis.”As importantly, prior to this study it wasn’t clear how to address the ancestry issue. But the new study provides clear direction. The team calculated that identification of the vast majority of ancestral variants can be performed successfully with a reference panel of less than 20 genomes—though it could well take more to identify a particular ancestry group’s rarest deviations. Of course, most people have more than one ancestry line, meaning that in practice a patient’s reference panel would need to include multiple reference groups.
Along with the paper’s lead author Torkamani, Schork is a founder of a company called Cypher Genomics that has licensed the Scripps Genome Adviser for disease-focused research. The teams in both industry and academia hope not only to continue idiopathic disease research, but also to apply similar principles to search for the causes of more complex congenital conditions. “The broader message of our work is that you have to take ancestry into account no matter what disease you’re studying,” said Schork.In addition to Torkamani and Schork, other authors on the paper, “Clinical Implications of Human Population Differences in Genome-wide Rates of Functional Genotypes,” are Phillip Pham, Ondrej Libiger, Vikas Bansal, Guangfa Zhang, Ashley Scott-Van Zeeland, Ryan Tewhey and Eric Topol (director of STSI). For more information on the paper (doi: 10.3389/fgene.2012.00211), see http://www.frontiersin.org/Applied_Genetic_Epidemiology/10.3389/fgene.2012.00211/abstract
Mika Ono | EurekAlert!
Rainbow colors reveal cell history: Uncovering β-cell heterogeneity
22.09.2017 | DFG-Forschungszentrum für Regenerative Therapien TU Dresden
The pyrenoid is a carbon-fixing liquid droplet
22.09.2017 | Max-Planck-Institut für Biochemie
A warming planet
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
22.09.2017 | Life Sciences
22.09.2017 | Medical Engineering
22.09.2017 | Physics and Astronomy